Intellia Therapeutics Company Insiders
NTLA Stock | USD 10.74 0.01 0.09% |
Intellia Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Intellia Therapeutics suggests that vertually all insiders are panicking. Intellia Therapeutics employs about 403 people. The company is managed by 24 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 16.79 employees per reported executive.
Nessan Bermingham CEO President CEO, Founder, Director |
Laura SeppLorenzino President Executive Vice President Chief Scientific Officer |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-07-02 | Michael P Dube | Disposed 2503 @ 9.95 | View | ||
2025-07-01 | Jesse Goodman | Disposed 1547 @ 9.23 | View | ||
2025-04-29 | Muna Bhanji | Disposed 265 @ 8.5 | View | ||
2025-01-29 | Muna Bhanji | Disposed 265 @ 9.97 | View | ||
2025-01-03 | Michael P Dube | Disposed 1372 @ 12.18 | View | ||
2025-01-02 | Eliana Clark | Disposed 556 @ 12.03 | View | ||
2024-10-02 | Michael P Dube | Disposed 2012 @ 19.01 | View |
Monitoring Intellia Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. Intellia Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3012) % which means that it has lost $0.3012 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5792) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 578.7 M, whereas Total Assets are forecasted to decline to about 743.3 M.As of July 6, 2025, Common Stock Shares Outstanding is expected to decline to about 55.8 M. The current year's Net Loss is expected to grow to about (405.4 M)
Intellia Therapeutics Workforce Comparison
Intellia Therapeutics is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 84,840. Intellia Therapeutics adds roughly 403 in number of employees claiming only tiny portion of equities under Health Care industry.
Intellia Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intellia Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bhanji Muna over two weeks ago Acquisition by Bhanji Muna of 11450 shares of Intellia Therapeutics at 8.37 subject to Rule 16b-3 | ||
Goff Brian over three months ago Acquisition by Goff Brian of 15409 shares of Intellia Therapeutics subject to Rule 16b-3 | ||
Schultes Birgit C over three months ago Insider Trading | ||
Clark Eliana over six months ago Disposition of 7422 shares by Clark Eliana of Intellia Therapeutics at 12.18 subject to Rule 16b-3 | ||
Clark Eliana over six months ago Disposition of 556 shares by Clark Eliana of Intellia Therapeutics at 12.03 subject to Rule 16b-3 | ||
Leonard John M over six months ago Disposition of 7850 shares by Leonard John M of Intellia Therapeutics subject to Rule 16b-3 | ||
Dube Michael P over six months ago Disposition of 2012 shares by Dube Michael P of Intellia Therapeutics at 19.01 subject to Rule 16b-3 | ||
Dulac Edward J Iii over six months ago Insider Trading |
Intellia Therapeutics Notable Stakeholders
An Intellia Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intellia Therapeutics often face trade-offs trying to please all of them. Intellia Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intellia Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Erik Sontheimer | Founder Board | Profile | |
Rodolphe MBA | Founder Board | Profile | |
Pr Marraffini | Founder Board | Profile | |
John MD | CEO President | Profile | |
Nessan Bermingham | President CEO, Founder, Director | Profile | |
Edward III | Chief President | Profile | |
Laura SeppLorenzino | Executive Vice President Chief Scientific Officer | Profile | |
Eliana Clark | Executive CTO | Profile | |
Birgit Schultes | Chief VP | Profile | |
JD Esq | General VP | Profile | |
Michael Dube | CAO VP | Profile | |
Jennifer Doudna | Founder Board | Profile | |
Derek Hicks | Executive Officer | Profile | |
Aron Stein | Senior Affairs | Profile | |
Andrew May | Founder Board | Profile | |
Yuanxin MD | Senior Medicine | Profile | |
Rachel Haurwitz | CoFounder | Profile | |
Kristy Wood | Senior Operations | Profile | |
Marika Amand | Senior Officer | Profile | |
Glenn CPA | CFO VP | Profile | |
David MD | Executive Officer | Profile | |
Dr JD | Senior Property | Profile | |
Derrick Rossi | Founder Board | Profile | |
Maria Natale | Senior Commercial | Profile |
About Intellia Therapeutics Management Performance
The success or failure of an entity such as Intellia Therapeutics often depends on how effective the management is. Intellia Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intellia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intellia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people.
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
Intellia Therapeutics Workforce Analysis
Traditionally, organizations such as Intellia Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intellia Therapeutics within its industry.Intellia Therapeutics Manpower Efficiency
Return on Intellia Therapeutics Manpower
Revenue Per Employee | 143.6K | |
Revenue Per Executive | 2.4M | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 21.6M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 22M |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |